China & AstraZeneca

China: The approval of ORPATHYS (savolitinib) in China addresses a significant unmet medical need for gastric cancer patients in the country, where gastric cancer is a leading cause of cancer death.

AstraZeneca: AstraZeneca, as HUTCHMED's partner, jointly developed and commercializes ORPATHYS (savolitinib). The approval in China for gastric cancer expands its market reach and reinforces its precision medicine strategy.

China: China highlighted regenerative agriculture partnerships and autonomous logistics solutions.

AstraZeneca: AstraZeneca featured an AI-powered drug discovery platform, advancing precision diagnostics and treatment.

China: Donald Trump acknowledged that his tariffs against China had previously hurt American farmers, who lost out on soybean sales, indicating potential for renewed trade tensions.

AstraZeneca: AstraZeneca, among other pharmaceutical companies, had previously announced investments in U.S. production due to the threat of tariffs, but the new, higher tariffs introduce further uncertainty.

AstraZeneca: AstraZeneca announced a significant investment of $15 billion in China through 2030 to expand its medicines manufacturing and research, demonstrating confidence in the Chinese market.

AstraZeneca: AstraZeneca's CEO, Pascal Soriot, is part of the business delegation, suggesting potential for increased pharmaceutical and healthcare sector cooperation with China.